On BH3 Mimetics and Ca2+ Signaling

被引:4
|
作者
Ferdek, Pawel E. [1 ]
Jakubowska, Monika A. [1 ]
机构
[1] Cardiff Univ, Cardiff Sch Biosci, Med Res Council Grp, Cardiff CF10 3AX, S Glam, Wales
基金
英国医学研究理事会;
关键词
Bcl-2; BH3; mimetics; calcium; cell signaling; clinical trials; protein-protein interaction; SELECTIVE BCL-2 INHIBITOR; ENDOPLASMIC-RETICULUM; CELL-DEATH; OUTER-MEMBRANE; APOPTOSIS; DOMAIN; PROTEINS; MODULATION; DISCOVERY; CHANNELS;
D O I
10.1002/ddr.21405
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
BH3 mimetics are anticancer agents that reproduce the spatial arrangement of the BH3 domain of Bcl-2 family proteins. Just like the BH3-only proteins, these compounds bind to the hydrophobic cleft of the pro-survival Bcl-2 members such as Bcl-2 or Bcl-xL, and disrupt their heterodimerization with pro-apoptotic Bax or Bak, sensitizing cells to chemotherapy. In recent years, it has become clear that Bcl-2 family proteins are engaged in regulation of intracellular Ca2+ homeostasis, including Ca2+ release from the intracellular stores as well as Ca2+ fluxes across the plasma membrane. Given that BH3 mimetics shift the balance between the prosurvival and proapoptotic Bcl-2 members, they might indirectly exert effects on intracellular Ca2+ signals. Indeed, it has been reported that some BH3 mimetics release Ca2+ from the intracellular stores causing Ca2+ overload in the cytosol. Therefore, the effects of any new BH3 mimetics on cellular Ca2+ homeostasis should be tested before these compounds progress to clinical trials. Drug Dev Res 78 : 313-318, 2017. (c) 2017 Wiley Periodicals, Inc.
引用
收藏
页码:313 / 318
页数:6
相关论文
共 50 条
  • [1] BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics
    Aaron, Rongqing
    Wang, Youzhen
    Qiu, Shumei
    Villalobos-Ortiz, Mariana
    Ryan, Jeremy
    Morris, Erick
    Halilovic, Ensar
    Letai, Anthony
    HAEMATOLOGICA, 2024, 109 (04) : 1253 - 1258
  • [2] BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics
    Pan, Rongqing Aaron
    Wang, Youzhen
    Qiu, Shumei
    Villalobos-Ortiz, Mariana
    Ryan, Jeremy
    Morris, Erick
    Halilovic, Ensar
    Letai, Anthony
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1253 - 1258
  • [3] Dynamic BH3 Profiling As Pharmacodynamic Biomarker for the Activity of BH3 Mimetics
    Pan, Rongqing
    Wang, Youzhen
    Qiu, Shumei
    Ryan, Jeremy
    Halilovic, Ensar
    BLOOD, 2020, 136
  • [4] BH3 Mimetics in Hematologic Malignancies
    Klener, Pavel
    Sovilj, Dana
    Renesova, Nicol
    Andera, Ladislav
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [5] BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
    Mariana Villalobos-Ortiz
    Jeremy Ryan
    Thelma N. Mashaka
    Joseph T. Opferman
    Anthony Letai
    Cell Death & Differentiation, 2020, 27 : 999 - 1007
  • [6] BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
    Villalobos-Ortiz, Mariana
    Ryan, Jeremy
    Mashaka, Thelma N.
    Opferman, Joseph T.
    Letai, Anthony
    CELL DEATH AND DIFFERENTIATION, 2020, 27 (03): : 999 - 1007
  • [7] The application of BH3 mimetics in myeloid leukemias
    Parry, Narissa
    Wheadon, Helen
    Copland, Mhairi
    CELL DEATH & DISEASE, 2021, 12 (02)
  • [8] BH3 Mimetics for the Treatment of Prostate Cancer
    Wolf, Philipp
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [9] IFN-y Signaling Sensitizes Melanoma Cells to BH3 Mimetics
    Ming, Zizhen
    Lim, Su Yin
    Stewart, Ashleigh
    Pedersen, Bernadette
    Shklovskaya, Elena
    Menzies, Alexander M.
    Carlino, Matteo S.
    Kefford, Richard F.
    Lee, Jenny H.
    Scolyer, Richard A.
    V. Long, Georgina
    Rizos, Helen
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (07) : 1246 - +
  • [10] Overview of BH3 mimetics in ovarian cancer
    Del Bufalo, Donatella
    Damia, Giovanna
    CANCER TREATMENT REVIEWS, 2024, 129